A drug, which has been developed from the results of cancer immunology research at the University of Southampton, has been shown to reduce the risk of follicular lymphoma progression.

Results from the phase III GALLIUM study, being presented at the American Society of Hematology (ASH) congress, showed combining obinutuzumab (Gazyva) with chemotherapy in the first-line setting reduced the risk of disease progression or death by 34 per cent versus rituximab (Rituxan) plus chemotherapy in patients with follicular lymphoma.

Obinutuzumab was developed by Roche following immunology research from University of Southampton scientists spanning more than a decade.

Read the full story on the University’s main site here.

 

This new type of antibody treatment for lymphoma has been developed from immunology research in Southampton which started more than 10 years ago, when we started to find out how these antibodies work. We have much more to do in many different types of cancer, but this is a great example of how discovery science can work through into better treatments for our patients

Peter Johnson, Professor of Medical Oncology at the University of Southampton